Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Deal Watch table for September 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during September 2014.

For an indepth analysis of these deals, read 'Pharma deals during September 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Sigma Aldrich /  Merck KGaA
Company acquisition
Laboratory supplies
17,000
Alios / J&J
Company acquisitionAnti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV
1,750
Lumara Health / Amag

Lumara Health / Perrigo
Company acquisition (excluding Perrigo products)
Maternal health business including orphan drug to reduce risk of preterm birth Makena

Three women's health products 
1,025

82
Merrimack / Baxter
Licence to commercialise1MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III
970
Infinity / AbbVie
Licence and collaborationIPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia 
805
Curevac / Boehringer Ingelheim
Licence and collaboration
Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer
601
Civitas / Acorda
Company acquisition
CVT-301 - Levodopa dry powder inhaler.  Phase IIb for treatment of Parkinsons + pulmonary delivery technology
525
AstraZeneca / Lilly
Licence and collaboration
Oral BACE inhibitor in phase I for Alzheimer's disease
500
Ambit Biosciences / Daiichi Sankyo
Company acquisition
Kinase inhibitor pipeline, lead compound quizartinib for AML in phase III
410
Aesica Pharmaceutical / Consort
Company acquisition
Aesica is a UK contract development and manufacturing company
374
Aspen / Mylan
Product acquisition2
Arixtra anticoagulant plus authorised generic version
300
Sutro / Merck KGaA
Licence and collaboration
Sutro's antibody drug conjugate technology for oncology
298
Rhizen / TG Therapeutics
Licence and collaboration3 (exercise of option)
TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies244
Seattle Genetics / Genmab
Licence and collaboration
Additional deal to use Seattle's antibody drug conjugate technology
211
Altor / Shenzhen Beike
Licence and collaboration4
ALT-803 an interleukin-15-based agonist in Phase I/II for treatment of various cancers
209
MyoKardia/ Sanofi
Licence and collaboration5
Three programmes for treatment of genetic forms of cardiomyopathy
200
Shasun / Strides Arcolab
Company acquisition
Shasun is an Indian API and generic company
200
Innovus / Sothema Labs

Innovus / Orimed
Licence to commercialise6

Licence to commercialise7
Natural oils to treat female sexual desire disorder (Zestra) and various penile disorders (EjectDelay, Sensum)
171

86
Isopure / GlanbiaCompany acquisition
Glanbia, US company selling premium branded sports nutrition powders and drinks153
NeuroVive / OnCoreLicence and collaboration
NVP018 an oral sangamide-based  2nd generation cyclophilin inhibitor for hepatitis B150

All deals are worldwide unless otherwise noted

1: Global excluding US and Taiwan
2: US only
3: Excludes India
4: China only
5: Excluding commercialisation in US
6: Middle East and Africa
7: Canada

The Deal Watch table is compiled by Medius Associates

13th October 2014

The Deal Watch table is compiled by Medius Associates

13th October 2014

From: Research, Sales

Share

Tags

Related content

More intelligence

Digital Handbook

Career advice

No results were found

Digital editions

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Quick links